BT-1718 is a synthetic peptide commercialized by Bicycle Therapeutics, with a leading Phase II program in Endometrial Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of BT-1718’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for BT-1718 is expected to reach an annual total of $17 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
BT-1718 is under development for the treatment of solid tumors including triple negative breast cancer, squamous non-small cell lung cancer, gastric, non-small cell lung cancer, bladder and sarcoma. It is administered through the intravenous route. The drug comprises of bicyclic peptide conjugated to the maytansinoid toxin. It is developed based on bicyclic peptide technology composed of peptides in combination with a matrix of different linkers for the delivery of a cytotoxic payload. The peptide acts by targeting cells expressing membrane type 1 matrix metalloproteinase (MMP14). It is developed based on bicycle toxin conjugate technology.
Bicycle Therapeutics Overview
Bicycle Therapeutics is a biotechnology company. It develops bicyclic peptides Medicines for the treatment of cancers and other debilitating diseases. The company’s Bicycle conjugates include BT1718, BT5528, and BT8009; and Immuno-Oncology offers BT7480, BT7401, and BT7455. Bicycle Therapeutics proprietary bicyclic peptide technology enables systematic cyclisation of peptides and helps to identify bicycles that provide antibody-like affinity and selectivity in a much smaller chemically synthesized molecule. The company operates with other biotechnology companies for the development of bicyclic peptide inhibitors for the treatment of ophthalmic diseases such as diabetic macular edema, renal elimination, versatility for multimerization and conjugation. It works in collaboration with Cancer Research UK(CRUK), AstraZeneca Plc in the areas of oncology, respiratory, cardiovascular, and metabolic diseases, among others. The company has operations in Massachusetts, the US. Bicycle Therapeutics is headquartered in Cambridge, Cambridgeshire, the UK.
The company reported revenues of (US Dollars) US$11.7 million for the fiscal year ended December 2021 (FY2021), an increase of 12.6% over FY2020. The operating loss of the company was US$65.6 million in FY2021, compared to an operating loss of US$52 million in FY2020. The net loss of the company was US$66.8 million in FY2021, compared to a net loss of US$51 million in FY2020. The company reported revenues of US$3 million for the third quarter ended September 2022, a decrease of 30.6% over the previous quarter.
For a complete picture of BT-1718’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.